Date: 16 July 2026
Time: 13:30 – 14:00 CET
Location: Online
The BStabG (GKV-Spargesetz) is not another incremental amendment – it is a structural reset of the AMNOG logic. The AMNOG guardrails may fall – but rebate agreements for patent-protected medicines, tighter price-volume rules and the “Deutschlandbonus” will redefine the negotiation surface. In this webinar, held immediately after the law was passed, Kintiga’s Market Access experts translated the new rules into strategic implications: where negotiation room opens, where financial exposure grows, and what Market Access leaders should prioritise now.
Your learning outcomes:
- A clear read on what the BStabG means for your portfolio You leave with a structured understanding of which measures affect which product archetypes – and where the strategic, not just operational, decisions sit.
- Concrete implications for your 2027 pricing and negotiation strategy You gain a working view of how possible adjustments like rebate tenders and the end of the guardrails change your preparation for the next AMNOG cycle – and what to adjust now.
- A pan-European perspective for regional and global discussions You can place the German changes in the wider European access context, like JCA, IRP exposure or launch sequencing, and bring a substantiated position into your internal alignment.
This webinar is designed for Market Access Managers and Directors in pharma and biotech – both in German affiliates preparing for the 2027 AMNOG cycle and in global or European teams shaping pricing, launch and portfolio decisions. It is equally relevant for Pricing, HEOR, Public Affairs and Commercial leads whose work intersects with the German reimbursement environment.
Presenters:
- Ingo Hantke, Director, Market Access
- Lydia Frick, Director, Market Access
- Sven Büscher, Manager, Market Access
If you would like to request a copy of this webinar recording, please use the form below:
